A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- safety & maximally tolerated dose
研究概览
简要总结
Ovarian cancer cannot grow without recruiting new blood vessels. Studies in humans have identified a novel cell population, termed vascular leukocytes (VLCs). While VLCs are not cancer cells, they support the growth of ovarian cancer cells by stimulating the growth of new blood vessels which provide the cancer with nutrients. VLCs make a protein termed CD52. An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the CD52 protein has been successfully used to treat certain lymphomas (a type of blood cell cancer) that make CD52 protein. The purpose of this study is to determine if Alemtuzumab given subcutaneously (under the skin)can be safely given to patients with ovarian, fallopian, or primary peritoneal cancers to kill VLCs and determine if Alemtuzumab, by eliminating VLCs, can restrict tumor growth or increase response rates to chemotherapy given after the discontinuation of chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have a diagnosis of histologically confirmed ovarian, fallopian or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy as documented by either:
- •Radiologic studies or
- •Rising CA125 levels on two independent measurements. If the patient's CA125 has fallen into a normal range, CA125 relapse will be defined as double the nadir CA
- •However, if the patients CA125 nadir had fallen to less than 10, then the measurements documenting recurrence or progression must be greater than
- •There is no limit on prior courses of chemotherapy.
- •Patients must have unidimensional measurable disease or elevated CA125
- •Age greater than 18 years.
- •ECOG performance status less tha 2 (Karnofsky 60%).
- •Life expectancy of greater than 12 weeks.
- •Patients must have adequate organ and marrow function
- •Ability to understand and the willingness to sign a written informed consent document. All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.
- •Timing guideline for pre-study labs and measurements:
- •All pre-study labs required for determination of eligibility are to be completed within 28 days of treatment Day
- •X-rays and/or scans used for tumor measurement to determine disease status are to be completed within 28 days of treatment Day
- •Women of all races and ethnic groups are eligible for this trial.
排除标准
- •Patients with known immunosuppressive diseases are excluded from this trial due to the known immunosuppressive nature of Alemtuzumab therapy.
- •Patients may not be receiving any other agents (investigational or otherwise) with therapeutic intent.
- •Patients with prior malignancy, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years.
- •Patients with a history of allergic reactions to Alemtuzumab or other humanized immunotherapeutics.
- •Patients with unresolved bacterial, fungal, or viral infections requiring active treatment. Patients may be registered two weeks after the conclusion of antibiotic or anti-viral therapy.
- •Patients with history of active CMV disease as Alemtuzumab therapy has been associated with CMV reactivation.
研究组 & 干预措施
one
干预措施: Alemtuzumab (Drug)
结局指标
主要结局
safety & maximally tolerated dose
时间窗: Maybe 2 years
次要结局
- Effectiveness of Alemtuzumab to eliminate VLCs.(Maybe 2 years)
- Assess molecular markers associated with reduction in VLCs.(Maybe 2 years)
- Anti-tumor activity measured by decline or stabilization of CA125(a protein that is a tumor marker)or radiological(ie. CT, MRI, X-Ray)improvement or improvement in progression free survival.(Maybe 2 years)
- Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.(Maybe 2 years)